Bristol Myers Squibb and company (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced the results of the three-year follow-up of the Phase 3 CheckMate -9ER Phase 3 trial evaluating Opdivo (nivolumab) plus Cabometyx (cabozantinib) in renal cancer.
Data demonstrated sustained response rate and survival benefits with the combination of nivolumab and cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC).
Additionally, a biomarker analysis showed sustained improvements in median progression-free survival (PFS) and overall survival (OS) with the combination of nivolumab and CABOMETYX, regardless of PD-L1 status.
No new safety signals were observed with prolonged follow-up.
Treatment with nivolumab in combination with cabometyx continued to show a 30% reduction in the risk of death and an improvement in median overall survival (OS) versus sunitinib (49.5 months vs. 35.5 months, respectively).
Median OS improved by 11.8 months from the previous data cutoff at 32.9 months median follow-up.
Progression-free survival (PFS) benefits were maintained, with the combination continuing to double the median PFS versus sunitinib (16.6 months vs. 8.4 months, respectively).
The objective response rate benefits were maintained, with nearly twice as many patients responding to nivolumab in combination with cabometyx versus sunitinib (55.7% vs. 28.4%).
Responses were longer lasting with the combination, with a median duration of response of 23.1 months compared to 15.2 months with sunitinib.
Complete response rates were also maintained, with 12.4% of those treated with nivolumab plus Cabometyx having CR versus 5.2% in the sunitinib arm.
Price Action: BMY shares were down 0.02% at $73.17, and EXEL shares were up 0.45% at $17.77 in late check on Tuesday.
Don’t miss out on real-time alerts on your actions – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster and better.
This article Bristol Myers Squibb-Exelixis Highlights Three-Year Follow-Up Data of Opdivo+Cabometyx Combination Therapy in Kidney Cancer originally appeared on Benzinga.com
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.